Eyenuk, Inc.
Medical Imaging & Radiology
Eyenuk is a global AI medical technology company leading in real-world AI eye screening for autonomous disease detection and predictive biomarkers.
About Eyenuk, Inc.
Eyenuk is a global AI medical technology company and the leader in real-world AI Eye Screening for autonomous disease detection.
Leadership Team
Key executives and founders sourced from public LinkedIn profiles.
Anyone with diabetes is vulnerable to blindness that can progress without any pain or discomfort. The condition, called diabetic retinopathy, is completely preventable if identified early, and yet it is the biggest cause of blindness in adult working age population. Eyenuk has developed EyeArt, a fully automated diabetic retinopathy screening software which will go a long way in preventing vision loss in this large growing population with diabetes. Kaushal Solanki is the CEO and Founder of Eyenuk, Inc., where he leads the product vision and execution, and works closely with the team on regulatory and commercial strategy/execution. With his market understanding, business sense, and focus on clinical relationships, he is setting a solid foundation for Eyenuk to thrive. Kaushal pioneered the development, prospective clinical validation, regulatory process, and early commercialization of EyeArt, Eyenuk's flagship autonomous artificial intelligence (AI) product for automated detection of diabetic retinopathy. The EyeArt AI System was developed with funding from the U.S. National Institutes of Health (NIH) and is validated by the U.K. National Health Service (NHS). Prior to founding Eyenuk, Kaushal was a research scientist at Mayachitra, Inc., where he led cutting-edge DARPA and DoD projects on image analysis from concept to commercialization. Kaushal has a doctorate in Electrical and Computer Engineering from University of California, Santa Barbara. An accomplished academic, Kaushal has published widely in international journals, with his work cited over 1000 times. He holds several issued and pending patents, and has co-authored an edited book and several book chapters.
Mission & Approach
AI Approach
computer vision, deep learning
Products & Solutions
EyeArt for AMD Detection
softwareAI-powered detection of age-related macular degeneration
An extension of the EyeArt platform specifically designed for autonomous detection of age-related macular degeneration (AMD) from retinal images. This product is part of Eyenuk's innovation pipeline.
EyeRead UWF
softwareUltra-widefield lesion analysis in retinal images
EyeRead UWF is a product under development designed to perform lesion analysis in ultra-widefield (UWF) retinal images. This tool aims to expand the capabilities of AI eye screening to wider field imaging.
EyeArt for Glaucoma Detection
softwareAI-powered detection of glaucoma from retinal imaging
An extension of the EyeArt platform specifically designed for autonomous detection of glaucoma from retinal images. This product is part of Eyenuk's innovation pipeline and has received EU MDR certification.
EyeMark
softwareAI system to accurately track retinopathy progression over time
EyeMark is a product under development designed to accurately track the progression of retinopathy in patients over time. This tool aims to help clinicians monitor disease advancement and make more informed treatment decisions.
Eyescreen Service
serviceAI-powered eye screening service for healthcare providers
A service offering that enables healthcare providers to implement AI eye screening in their clinical workflow. The service integrates with retinal cameras to provide automated screening capabilities for diabetic retinopathy and other eye conditions.
EyeArt AI Eye Screening System
FlagshipsoftwareAutonomous AI detection of diabetic retinopathy, AMD, and glaucoma from retinal images
EyeArt is the first FDA cleared AI technology for autonomous detection of both more than mild and vision-threatening diabetic retinopathy. The system autonomously analyzes patient's retinal images acquired using an integrated fundus camera, robustly detects signs of disease, and returns an easy-to-read report in under 60 seconds. It has been tested on over half a million patient visits globally with over two million images collected in real-world clinical environments.
Customer Success Stories
National Health System (Denmark)
government
World's first national health system deployment of autonomous AI eye screening technology
University of Illinois at Chicago
hospital
Pivotal, prospective, multi-center clinical trial for diabetic retinopathy detection
EyePACS
health system
Large scale validation of EyeArt AI system for diabetic retinopathy screening
Hiring Activity
View Open Roles →Product & Market
Product Stage
enterprisePrimary Market
providersCompany Details
- Founded
- 2010
- Headquarters
- Woodland Hills, CA, USA
- Employees
- 30
- Stage
- series a
- Profile last updated
- June 22, 2026
Category
Medical Imaging & RadiologyOfficial Sources
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSocial & Media
X / Twitter
View Profile →Latest Updates
Eyenuk Secures World’s First National Health System Deployment of Autonomous AI Eye Screening Technology
Los Angeles, USA and Copenhagen, Denmark – Sept. 17, 2025 – Eyenuk, a global leader in AI-powered eye screening, today announced that its EyeArt® AI Eye Screening System has been…
Sep 17, 2025
Read more →
Eyenuk Appoints Mads Dall as Chairman of the Board and Gaurav Agarwal as Chief Executive Officer
Los Angeles, Jan. 06, 2025 — Eyenuk, a global artificial intelligence (AI) digital health company and leader in real-world applications for AI Eye Screening™ and AI Predictive Biomarkers™, today announced…
Jan 6, 2025
Read more →Eyenuk Supports Federal Efforts to Promote Nationwide Adoption of Interoperable Standards for Ophthalmic Imaging Data
LOS ANGELES, November 28th, 2023 – Eyenuk, Inc., a leading global digital health company specializing in artificial intelligence (AI), today stands shoulder to shoulder with the National Eye Institute (NEI),…
Nov 28, 2023
Read more →
New FDA Clearance Makes Eyenuk the First Company with Multiple Cameras for Autonomous AI Detection of Diabetic Retinopathy
This clearance expands the label of its flagship product, the EyeArt® AI system, broadening the choice for primary care clinics to screen people with diabetes Company’s FDA clearance also includes…
Jun 22, 2023
Read more →
Eyenuk Secures the First European Union MDR Certification for Autonomous AI Detection of Diabetic Retinopathy, Age-Related Macular Degeneration, and Glaucoma
The approval allows Eyenuk’s AI eye screening system, already approved for detection of diabetic retinopathy, to aid millions of additional patients at risk for vision loss LOS ANGELES, January 31,…
Jan 31, 2023
Read more →Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as employee counts and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.